公开(公告)号：US20200247801A1

公开(公告)日：2020-08-06

申请号：US16753630

申请日：2018-10-04

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tomoaki Hasui ,  Shinji NAKAMURA ,  Satoshi MIKAMI ,  Tohru YAMASHITA

IPC: C07D471/04 ,  C07D413/10 ,  C07D407/12 ,  C07D413/14

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20160060273A1

公开(公告)日：2016-03-03

申请号：US14775265

申请日：2014-03-13

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shizuo KASAI ,  Masaki OGINO ,  Ryo MIZOJIRI ,  Takeshi YAMASAKI ,  Hideki HIROSE ,  Nobuyuki TAKAKURA ,  Tohru YAMASHITA ,  Sachie MORIMOTO ,  Takashi NAKAHATA ,  Asato KINA

IPC: C07D498/10

CPC classification number: C07D498/10

Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.

Abstract translation: 提供具有下式（1）表示的化合物或其盐，其具有SSTR5拮抗作用：其中每个符号具有与说明书中相同的定义。

公开(公告)号：US20230278999A1

公开(公告)日：2023-09-07

申请号：US17819818

申请日：2022-08-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tomoaki HASUI ,  Shinji NAKAMURA ,  Satoshi MIKAMI ,  Tohru YAMASHITA

IPC: C07D471/04 ,  C07D407/12 ,  C07D413/10 ,  C07D413/14

CPC classification number: C07D471/04 ,  C07D407/12 ,  C07D413/10 ,  C07D413/14

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like.
The present invention relates to a compound represented by the formula (I):





wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20200270243A1

公开(公告)日：2020-08-27

申请号：US16753613

申请日：2018-10-04

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinji NAKAMURA ,  Satoshi MIKAMI ,  Tomoaki HASUI ,  Tohru YAMASHITA ,  Shinji MORIMOTO ,  Hidekazu TOKUHARA ,  Norio OYABU ,  Masami YAMADA ,  Atsuko OCHIDA ,  Kazuaki TAKAMI ,  Xin LIU

IPC: C07D471/04 ,  C07D519/00 ,  C07D487/04 ,  A61K9/20

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.